Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 11/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28639329 | 0.97 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL5178216 | 0.97 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11830303 | 0.97 | TSHR (0.41) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL9808534 | 0.97 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL8685461 | 0.97 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL7613996 | 0.97 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL8685667 | 0.97 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL8687488 | 0.97 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11831224 | 0.94 | TSHR (0.47) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11832302 | 0.94 | TSHR (0.47) | TSHRTHRBFDPSSMPD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280753-A1 | PROCESS FOR PREPARATION OF R-1-(ARYLOXY)PROPAN-2-OL | Rhodia/Chirex, Inc. (US) | 2003-02-05 | — | — | EP | claimed |
| US-6448449-B2 | RING OPENING OF (R)-PROPYLENE OXIDE WITH ARYLTRIMETHYLSILYL ETHER IN THE PRESENCE OF AN OPTICALLY ACTIVE CATALYST; REACTING WITH AN ALCOHOL IN THE PRESENCE OF AN ACID; REACTING THE REGIOISOMERIC MIXTURE WITH A TRIARYLMETHYL HALILE; | RHODIA CHIREX, INC. | 2002-09-10 | — | — | US | claimed |
| US-20020007090-A1 | Process for preparation of (R)-1- (aryloxy)propan-2-ol | RHODIA CHIREX, INC. | 2002-01-17 | — | — | US | claimed |
| WO-2001081286-A1 | PROCESS FOR PREPARATION OF R-1-(ARYLOXY)PROPAN-2-OL | RHODIA/CHIREX, INC. (US) | 2001-11-01 | — | — | WO | claimed |
| WO-1993000395-A1 | ADDITIVES WHICH STABILIZE HYDROHALOCARBON BLOWING AGENT IN POLYURETHANE AND POLYISOCYANURATE FOAM FORMULATIONS DURING POLYMERIZATION | ALLIED-SIGNAL INC. (US) | 1993-01-07 | — | — | WO | claimed |
| US-5137929-A | Additives which stabilize hydrohalocarbon blowing agent in polyurethane and polyisocyanurate foam formulations during polymerization | ALLIED-SIGNAL INC. (US) | 1992-08-11 | — | — | US | claimed |
| WO-2024081372-A1 | PROCESSES FOR THE PREPARATION OF THE AGENT-LINKER CONJUGATE CL2A-SN-38 AND THE IMMUNOCONJUGATES SACITUZUMAB GOVITECAN AND LABETUZUMAB GOVETICAN | GILEAD SCIENCES, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11034687-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-107406440-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20200308166-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3271355-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-10723729-B2 | BACE1 inhibitors | Hoffmann-Le Roche Inc. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190337936-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-11-07 | — | — | US | disclosed |
| US-4670175-A | APROTIC SOLVENT WITH A HEXAFLUOROPHOSPHATE OF A TETRAALKYL AMMONIUM, DIAZONIUM, OR TRIARYLCARBONYL GROUP | NIPPON CHEMI-CON CORPORATION (JP) | 1987-06-02 | — | — | US | disclosed |
| US-4668777-A | POLYNUCLEOTIDE INTERMEDIATES | UNIVERSITY PATENTS, INC. (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0210657-A1 | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-02-04 | — | — | EP | disclosed |
| EP-0061746-B1 | PHOSPHORAMIDITE COMPOUNDS AND THEIR USE IN PRODUCING OLIGONUCLEOTIDES | UNIVERSITY PATENTS, INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| US-4500707-A | Nucleosides useful in the preparation of polynucleotides | UNIVERSITY PATENTS, INC. (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0061746-A1 | Phosphoramidite compounds and their use in producing oligonucleotides | UNIVERSITY PATENTS, INC. (US) | 1982-10-06 | — | — | EP | disclosed |
| US-4171426-A | ANIONIC CATALYST, 2-PYRROLIDONE OR E-CAPROLACTAM | CHEVRON RESEARCH COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337936-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | TSHR 4825/4885THRB 2942/4885FDPS 1864/4885 |
| US-20020007090-A1 | Process for preparation of (R)-1- (aryloxy)propan-2-ol | TOP1, POLN, RIF1 | TSHR 845/4885THRB 1193/4885FDPS 493/4885 |
| US-20200308166-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | TSHR 4825/4885THRB 2942/4885FDPS 1864/4885 |
| US-10723729-B2 | BACE1 inhibitors | BACE1, BACE2, APP | TSHR 4825/4885THRB 2942/4885FDPS 1864/4885 |
| US-11034687-B2 | BACE1 inhibitors | BACE1, BACE2, APP | TSHR 4825/4885THRB 2942/4885FDPS 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.